Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy
Status:
Completed
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Megestrol is a semisynthetic progesterone derivatives, have promote anabolic effects. Can
improve appetite, weight gain, and improve bone marrow suppression, increase the tolerance
put, chemotherapy, improve the quality of life, is widely used in tumor radiation and
chemotherapy of terminally ill patients. But because of its vascular embolization, vaginal
bleeding, arrhythmia and other serious complications, there is no unified standard.
The purpose of this study was to evaluate megestrol in esophageal squamous carcinoma radical
chemoradiation curative effect and side effects, for rational use in the process of radiation
and chemotherapy megestrol provide guidelines. A total of 210 patients will be accrued from
China.The primary end point is quality of life (will be evaluated by EORTC QLQ-C30); the
secondary end point is the pathological response after treatment and adverse events.
Phase:
Phase 3
Details
Lead Sponsor:
The First Affiliated Hospital of Henan University of Science and Technology